Full history for every metric is available with a Kvantra account
Evoke Pharma, Inc. (EVOK)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 2 | 3 | 5 | 10 | 14 |
| Operating profit | $m | -5 | -5 | |||||
| Net profit | $m | -7 | -13 | -9 | -8 | -8 | -5 | -5 |
| EPS reported | $ | -2.81 | -2.38 | |||||
| Operating cashflow per share | $ | -2.87 | -0.82 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -2.87 | -0.82 | |||||
| Free cash flow | $m | -5 | -3 | |||||
| Net debt | $m | -9 | -7 | |||||
| Book value equity | $m | 7 | 3 | |||||
| Book value per share | $ | 3.69 | 1.31 | |||||
| Number of shares | m | 1.91 | 2.56 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.20 | 5.64 | |||||
| P/S LTM | x | 0.82 | 1.31 | |||||
| P/FCF LTM | x | -1.54 | -5.70 | |||||
| EV/EBITDA LTM | x | -0.04 | -2.62 | |||||
| EV/Sales LTM | x | -0.00 | 0.86 | |||||
| Earnings Yield LTM | % | -63.56% | -14.34% | |||||
| FCF Yield | % | -64.83% | -17.55% | |||||
| Quality | ||||||||
| ROE | % | -76.05% | -89.12% | |||||
| ROIC | % | -42.66% | -47.18% | |||||
| Operating margin | % | -50.77% | -35.97% | |||||
| Gross margin | % | 96.52% | 97.20% | |||||
| FCF/Sales | % | -53.26% | -18.75% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +97.84% | +67.40% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.06 | -0.65 | |||||
| Net Debt/EBITDA | x | -23.88 | 1.77 | |||||
| EBIT/Net interest | x | -10.38 | -10.69 | |||||
| Net debt/market cap | % | -102.09% | -34.71% | |||||
| Net debt/Equity | x | -1.22 | -1.96 | |||||
| Gross debt/equity | x | 0.73 | 1.52 | |||||
Company overview
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Evoke Pharma, Inc. (EVOK)
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free